title: Insulin-like growth factor II allows prolonged blood glucose normalization with a reduced islet cell mass transplantation.
abstract: IGF-II has been reported to decrease neonatal islet cell apoptosis and in vitro adult islet cell necrosis and apoptosis, but the usefulness of IGF-II in a transplantation setting is unknown. We evaluated the effect of in vitro IGF-II incubations on microencapsulated rat islet survival both in vitro and in minimal mass transplantations into diabetic mice. After 6 d in culture, fresh examinations, histology, fluorescence microscopy, sodium 3'-[1-(phenyl-amino-carbonyl)-3,4-tetrazolium]-bis (4-methoxy-6-nitro)-benzene sulfonic acid hydrate assay, and apoptosis studies all indicated that IGF-II significantly improves islet cell viability in a dose-dependent fashion. IGF-II 100 ng/ml and 500 ng/ml induced a 51% and 83% increase of viable islets (P = 0.052, P < 0.01). A 20%, 29%, and 33% reduction of the apoptotic index was observed with 50, 100, and 500 ng/ml incubations respectively (P < 0.05; P < 0.005; P < 0.001). Ten weeks after transplantation of 150 encapsulated rat islet equivalents incubated with IGF-II 500 ng/ml, 80% of diabetic mice were normoglycemic. Without IGF-II preincubation, only 8% of the recipients remained normoglycemic with the transplantation of 150 islets and 42% with 300 islets (P < 0.05). In conclusion, IGF-II promotes islet cell survival, and allows successful transplantation using a smaller number of islets.
authors.affiliation: Université de Montréal, Guy-Bernier Research Centre, Maisonneuve-Rosemont Hospital, 5415 Boulevard de l'Assomption, Montréal, Québec, Canada H1T 2M4.
authors.forename: Robert
authors.initials: R
authors.lastname: Robitaille
authors.forename: Julie
authors.initials: J
authors.lastname: Dusseault
authors.forename: Nathalie
authors.initials: N
authors.lastname: Henley
authors.forename: Lawrence
authors.initials: L
authors.lastname: Rosenberg
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Hallé
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001786:Blood Glucose / Q000378:metabolism*; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000601:surgery; D006085:Graft Survival / Q000187:drug effects*; D066298:In Vitro Techniques; D007202:Indicators and Reagents; D007335:Insulin-Like Growth Factor II / Q000494:pharmacology*; D007515:Islets of Langerhans / Q000166:cytology / Q000187:drug effects; D016381:Islets of Langerhans Transplantation; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D051381:Rats; D017208:Rats, Wistar; D013778:Tetrazolium Salts
chemical_list: D001786:Blood Glucose; D007202:Indicators and Reagents; D013778:Tetrazolium Salts; C059087:2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-((phenylamino)carbonyl)-2H-tetrazolium hydroxide; D007335:Insulin-Like Growth Factor II